Of these, the pretreatment mGPS, a score combining CRP and serum albumin levels, better predicts cancer survival compared with the peripheral blood cell count-based prognostic scores (e.g., NLR and PLR) (Dutta et al., 2011). This evidence concerns the gene ALB and cancer.